שווי כולל של החברה: Alvotech (ALVO)

Alvotech (ALVO) is optimizing expenses by outsourcing clinical trials and drug manufacturing to third-party contractors. Primary growth is driven by the expansion of biosimilars in Western countries, while the current enterprise value stands at 3112.83. The business relies on partnerships with global industry leaders to expand distribution. The share price visualized below on GURU.Markets allows for a real-time assessment of the company's market dynamics.

An investment audit of Alvotech requires an analysis of the enterprise value, which is calculated by summing the market capitalization and debt obligations minus cash and cash equivalents. This net market price of the business reflects the actual cost of acquiring the issuer, taking into account the capital intensity of geothermal-powered biosimilar production in Iceland and the company's current debt load.